The latest biotech news

News and Trends 24 Oct 2017

French Biotech‘s Bacterial Product is Ready to Enter the Anti-Aging Skincare Market

Montpellier-based Deinove has developed a bacterial anti-aging skincare product, which has shown its safety and healing capacity in studies so far. Deinove specializes in high-value compounds from rare bacteria, in particular, the Deinococcus genus. It has announced that it will launch its first cosmetic product into the anti-aging skincare market in 2018, which is based on a […]

October 24, 2017 - 2 minutesmins - By Alex Dale

News and Trends 23 Oct 2017

FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation

TiGenix’s candidate for a nasty Crohn’s disease complication received orphan drug designation after agreeing on a global Phase III trial. TiGenix exploits the anti-inflammatory properties of donor-derived stem cells to treat diseases. One of its candidates, Cx601, is targeted at a complication of Crohn’s disease – a nasty inflammatory condition affecting the intestine. Cx601 met efficacy and safety […]

October 23, 2017 - 2 minutesmins - By Alex Dale

News and Trends 23 Oct 2017

Transgene‘s Hepatitis B Vaccine Does the Business at Phase I

The French biotech‘s hepatitis B vaccine has demonstrated good efficacy and safety, suggesting it could provide effective protection from the virus. Biotech veteran, Transgene, specializes in viral-based immunotherapies for cancers and infectious diseases. One of its targets, hepatitis B, is a potentially fatal liver infection caused by the hepatitis B virus (HBV). Today, it has […]

October 23, 2017 - 2 minutesmins - By Alex Dale

News and Trends 23 Oct 2017

Swiss Biotech Rakes in $200M to Accelerate Antibody-based Cancer Treatments

ADC Therapeutics has received massive private funding to progress two of its lead candidates for cancer through clinical trials. ADC Therapeutics, based in Lausanne, Switzerland, specializes in developing antibody-drug conjugates (ADCs) for the treatment of cancer. The technology uses the specificity of antibodies to deliver a therapeutic agent to target cells only. The biotech has […]

October 23, 2017 - 3 minutesmins - By Alex Dale

News and Trends 23 Oct 2017

Peanut Allergy Trial Fails but French Biotech Keeps Pushing for Approval

DBV Technologies plans to go ahead with its peanut allergy treatment despite its failure to meet a primary endpoint in Phase III. Last Friday, DBV Technologies released the results of a Phase III trial that was key to the approval of a treatment to reduce peanut allergy in children. After 12 months, 35% of children […]

October 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Oct 2017

A Peptide Reduces Bleeding in Surgery in Phase II Trials

Ergomed has announced positive results in Phase II with PeproStat, a peptide solution to stop bleeding during surgery faster. In a Phase II study that recruited 169 patients across 16 European hospitals, London-based Ergomed has demonstrated that itspipeline’s lead candidate, PeproStat, can reduce the time to achieve hemostasis, that is, for the bleeding to stop, […]

October 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Oct 2017

Leading Pharma-Academic Partnership Unravels the Mystery of a Major Cancer Gene

The PTEN gene controls cell growth and behavior, with its loss implicated in cancer. AstraZeneca and Babraham have collaborated to improve our understanding of how this happens. The Babraham Institute, Cambridge, UK and AstraZeneca have unveiled research that helps us to better understand a key cancer gene, PTEN – reportedly the second most altered gene in cancers. […]

October 20, 2017 - 2 minutesmins - By Alex Dale

News and Trends 19 Oct 2017

Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech

Inbiomotion has published the results of a Phase III study looking at its MAFTest to personalized approaches to the disease. Inbiomotion, based in Barcelona’s biotech hub, works on a highly selective biomarker for breast cancer. A Phase III study demonstrated that breast cancer patients that would benefit from zoledronic acid therapy can be selected, helping clinicians offer […]

October 19, 2017 - 3 minutesmins - By Alex Dale

News and Trends 19 Oct 2017

Dutch Biotech plans Pivotal Clinical Trial with First Gene Therapy for Hemophilia

uniQure is getting ready to start a Phase III clinical trial in 2018 with a new version of its gene therapy for hemophilia B. uniQure has officially launched a plan to bring the first gene therapy for hemophilia to the market. After multiple meetings with the FDA and the EMA, the Dutch biotech has received permission […]

October 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2017

The FDA Approves a Second CAR-T Therapy, Cheaper than Novartis’

Gilead’s CAR-T cell therapy Yescarta has been approved by the FDA, making it the first competitor for Novartis’ CAR-T Kymriah. Yescarta (axicabtagene ciloleucel, or axi-cel for short) has become the second CAR-T therapy to be approved in the US. The FDA has authorized its use to treat aggressive B-cell non-Hodgkin lymphoma in patients for whom at least two […]

October 19, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2017

Meet some of the Hottest Startups of 2017!

– This article was originally published on 27th September 2017. This is an updated version – Large events, like BIO-Europe offer startup slams, which give entrepreneurs the opportunity to present their company at the conference. Not only does a slam create exposure for the startup, but it also allows young companies to receive valuable feedback from […]

October 19, 2017 - 7 minutesmins - By External Contributor

News and Trends 19 Oct 2017

Austrian Researchers Identify Target for Treatment of Multiple Sclerosis

Multiple sclerosis is the most common disease of the CNS in young adults. Researchers may have stumbled across a new approach for its treatment. Researchers at the Medical University of Vienna have identified a target for the treatment of multiple sclerosis (MS). The research, published in the Journal of Autoimmunity, found that histone deacetylases (HDACs) play […]

October 19, 2017 - 3 minutesmins - By Alex Dale

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

French Biotech‘s Bacterial Product is Ready to Enter the Anti-Aging Skincare Market

FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation

Transgene‘s Hepatitis B Vaccine Does the Business at Phase I

Swiss Biotech Rakes in $200M to Accelerate Antibody-based Cancer Treatments

Peanut Allergy Trial Fails but French Biotech Keeps Pushing for Approval

A Peptide Reduces Bleeding in Surgery in Phase II Trials

Leading Pharma-Academic Partnership Unravels the Mystery of a Major Cancer Gene

Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech

Dutch Biotech plans Pivotal Clinical Trial with First Gene Therapy for Hemophilia

The FDA Approves a Second CAR-T Therapy, Cheaper than Novartis’

Meet some of the Hottest Startups of 2017!

Austrian Researchers Identify Target for Treatment of Multiple Sclerosis

Subscribe to our newsletter to get the latest biotech news!